Crescent Biopharma (CBIO) Income from Continuing Operations (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Income from Continuing Operations of 24837000.0 for Q2 2026, down 13.98% year-over-year from 28874685.48 in Q2 2025, and up 67.44% quarter-over-quarter from 76282000.0 in Q1 2026.
Crescent Biopharma (CBIO) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Income from Continuing Operations for 14 consecutive years, with 24837000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 13.98% year-over-year to 24837000.0; the TTM figure through Jun 2026 stood at 230938000.0 (down 345.61% YoY), while the FY2025 annual figure was 153942000.0, down 306.18% from the prior year.
- Income from Continuing Operations rose to 24837000.0 in Q2 2026 per CBIO's latest filing, from 76282000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2343736.0 in Q1 2025 and bottomed at 90397000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 21510186.89 across 5 years, with a median of 10548008.5 in 2023.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations surged 78.17% — and 2026, when it sank 3154.72%.
- Crescent Biopharma's Income from Continuing Operations stood at 10244355.0 in 2022, then grew by 11.38% to 9078640.0 in 2023, then sank by 96.8% to 17867000.0 in 2024, then sank by 405.94% to 90397000.0 in 2025, then soared by 72.52% to 24837000.0 in 2026.
- Business Quant data shows CBIO's Income from Continuing Operations at 24837000.0 in Q2 2026, 76282000.0 in Q1 2026, and 90397000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | -24.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.84 Mn |
| Mar 31, 2026 | -76.28 Mn |
| Dec 31, 2025 | -90.40 Mn |
| Sep 30, 2025 | -24.61 Mn |
| Jun 30, 2025 | -51.31 Mn |
| Mar 31, 2025 | -2.30 Mn |
| Dec 31, 2024 | -17.87 Mn |
| Sep 30, 2024 | -9.82 Mn |
| Jun 30, 2024 | -10.10 Mn |
| Mar 31, 2024 | -10.74 Mn |
| Dec 31, 2023 | -9.08 Mn |
| Sep 30, 2023 | -9.20 Mn |
| Jun 30, 2023 | -8.26 Mn |
| Mar 31, 2023 | -10.36 Mn |
| Dec 31, 2022 | -10.24 Mn |
| Sep 30, 2022 | -8.52 Mn |
| Jun 30, 2022 | -13.27 Mn |
| Mar 31, 2022 | -14.65 Mn |
| Dec 31, 2021 | -17.42 Mn |
| Sep 30, 2021 | -17.33 Mn |